Literature DB >> 34130697

Functional interplay between long non-coding RNAs and the Wnt signaling cascade in osteosarcoma.

Jieyu He1, Lin Ling2, Zhongyue Liu2, Xiaolei Ren2,3, Lu Wan2, Chao Tu4,5, Zhihong Li6,7.   

Abstract

Osteosarcoma is a common and highly malignant bone tumor among children, adolescents and young adults. However, the underlying molecular mechanisms remain largely unexplored. LncRNAs are transcripts with no or limited protein-coding capacity in human genomes, and have been demonstrated to play crucial functions in initiation, progression, therapeutic resistance, recurrence and metastasis of tumor. Considerable studies revealed a dysregulated lncRNA expression pattern in osteosarcoma, which may act as oncogenes or suppressors to regulate osteosarcoma progression. Wnt signaling pathway is an important cascade in tumorigenesis by modulation of pleiotropic biological functions including cell proliferation, apoptosis, differentiation, stemness, genetic stability and chemoresistance. Hyperactivation or deficiency of key effectors in Wnt cascade is a common event in many osteosarcoma patients. Recently, increasing evidences have suggested that lncRNAs could interplay with component of Wnt pathway, and thereby contribute to osteosarcoma onset, progression and dissemination. In this review, we briefly summarize Wnt signaling-related lncRNAs in osteosarcoma progression, aiming to gain insights into their underlying crosstalk as well as clinical application in osteosarcoma therapeutic modalities.

Entities:  

Keywords:  Drug resistance; LncRNA; Osteosarcoma; Stemness; Wnt; β-catenin

Year:  2021        PMID: 34130697     DOI: 10.1186/s12935-021-02013-8

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  172 in total

Review 1.  New insights into molecular and cellular mechanisms of zoledronate in human osteosarcoma.

Authors:  Ko-Hsiu Lu; Eric Wun-Hao Lu; Chiao-Wen Lin; Jia-Sin Yang; Shun-Fa Yang
Journal:  Pharmacol Ther       Date:  2020-06-18       Impact factor: 12.310

Review 2.  New targets and approaches in osteosarcoma.

Authors:  Jonathan Gill; Manpreet K Ahluwalia; David Geller; Richard Gorlick
Journal:  Pharmacol Ther       Date:  2012-09-14       Impact factor: 12.310

3.  Diagnostic and Prognostic Significance of Dysregulated Expression of Circular RNAs in Osteosarcoma.

Authors:  Chenghao Zhang; Jieyu He; Lin Qi; Lu Wan; Wanchun Wang; Chao Tu; Zhihong Li
Journal:  Expert Rev Mol Diagn       Date:  2021-01-22       Impact factor: 5.225

4.  The Value of LncRNA BCAR4 as a Prognostic Biomarker on Clinical Outcomes in Human Cancers.

Authors:  Chao Tu; Xiaolei Ren; Jieyu He; Chenghao Zhang; Ruiqi Chen; Wanchun Wang; Zhihong Li
Journal:  J Cancer       Date:  2019-10-15       Impact factor: 4.207

5.  Silencing of long-non-coding RNA ANCR suppresses the migration and invasion of osteosarcoma cells by activating the p38MAPK signalling pathway.

Authors:  Bo Liu; Hongyan Zhao; Lili Zhang; Xuefeng Shi
Journal:  BMC Cancer       Date:  2019-11-14       Impact factor: 4.430

Review 6.  Long noncoding RNAs in osteosarcoma via various signaling pathways.

Authors:  Jinming Han; Xiaohan Shen
Journal:  J Clin Lab Anal       Date:  2020-04-06       Impact factor: 2.352

Review 7.  Novel molecular insights and new therapeutic strategies in osteosarcoma.

Authors:  Babak Otoukesh; Bahram Boddouhi; Mehdi Moghtadaei; Peyman Kaghazian; Maria Kaghazian
Journal:  Cancer Cell Int       Date:  2018-10-16       Impact factor: 5.722

8.  TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model.

Authors:  Brice Moukengue; Hannah K Brown; Céline Charrier; Séverine Battaglia; Marc Baud'huin; Thibaut Quillard; Therese M Pham; Ioannis S Pateras; Vassilis G Gorgoulis; Thomas Helleday; Dominique Heymann; Ulrika Warpman Berglund; Benjamin Ory; Francois Lamoureux
Journal:  EBioMedicine       Date:  2020-03-07       Impact factor: 8.143

Review 9.  Melatonin: an anti-tumor agent for osteosarcoma.

Authors:  Hadis Fathizadeh; Hamed Mirzaei; Zatollah Asemi
Journal:  Cancer Cell Int       Date:  2019-11-29       Impact factor: 5.722

10.  Upregulated expression of LncRNA nicotinamide nucleotide transhydrogenase antisense RNA 1 is correlated with unfavorable clinical outcomes in cancers.

Authors:  Chenghao Zhang; Xiaolei Ren; Zhongyue Liu; Chao Tu
Journal:  BMC Cancer       Date:  2020-09-14       Impact factor: 4.430

View more
  6 in total

Review 1.  Diabetes mellitus susceptibility with varied diseased phenotypes and its comparison with phenome interactome networks.

Authors:  Madhusmita Rout; Bhumandeep Kour; Sugunakar Vuree; Sajitha S Lulu; Krishna Mohan Medicherla; Prashanth Suravajhala
Journal:  World J Clin Cases       Date:  2022-06-26       Impact factor: 1.534

Review 2.  Exosomal MiRNAs in Osteosarcoma: Biogenesis and Biological Functions.

Authors:  Jinxin Tang; Jieyu He; Chengyao Feng; Chao Tu
Journal:  Front Pharmacol       Date:  2022-05-03       Impact factor: 5.988

3.  MTHFR Polymorphism Is Associated With Severe Methotrexate-Induced Toxicity in Osteosarcoma Treatment.

Authors:  Wenchao Zhang; Zhongyue Liu; Zhimin Yang; Chengyao Feng; Xiaowen Zhou; Chao Tu; Zhihong Li
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 6.244

4.  The Clinical Significance and Potential Molecular Mechanism of Upregulated CDC28 Protein Kinase Regulatory Subunit 1B in Osteosarcoma.

Authors:  Chaohua Mo; Le Xie; Chang Chen; Jie Ma; Yingxin Huang; Yanxing Wu; Yuanyuan Xu; Huizhi Peng; Zengwei Chen; Rongjun Mao
Journal:  J Oncol       Date:  2021-12-10       Impact factor: 4.375

Review 5.  Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma.

Authors:  Camille Jubelin; Javier Muñoz-Garcia; Denis Cochonneau; Emilie Moranton; Marie-Françoise Heymann; Dominique Heymann
Journal:  Cancer Drug Resist       Date:  2022-02-16

Review 6.  Emerging Applications of Deep Learning in Bone Tumors: Current Advances and Challenges.

Authors:  Xiaowen Zhou; Hua Wang; Chengyao Feng; Ruilin Xu; Yu He; Lan Li; Chao Tu
Journal:  Front Oncol       Date:  2022-07-19       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.